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Early neonatal vitamin A supplementation and
infant mortality: an individual participant data
meta-analysis of randomised controlled trials
Neonatal Vitamin A Supplementation Evidence group
Abstract
Background Biannual vitamin A supplementation is
a well-established survival tool for preschool children
6 months and older in vitamin A deficient populations
but this schedule misses the opportunity to intervene
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on most young infant deaths. Randomised trials of
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neonatal vitamin A supplementation (NVAS) in the first
few days of life to assess its impact on under 6-month
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and pooled the primary outcomes of mortality from
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supplementation through 6 and 12 months of age
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using random effects models and meta-regression. One
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investigator withdrew but allowed use of the data.
Findings Overall there was no effect of NVAS on
infant survival through 6 (risk ratio (RR) 0.97; 95% CI
0.89 to 1.06) or 12 months of age (RR 1.00; 95% CI
0.93 to 1.08) but results varied by study population
characteristics. NVAS significantly reduced 6-month
mortality among the trials conducted in Southern
Asia (RR 0.87; 95% CI 0.77 to 0.98), in contexts with
moderate or severe vitamin A deficiency (defined as 10%
or higher proportion of women with serum retinol <0.7
µmol/L or 5% or more women with night blindness)
(RR 0.87; 95% CI 0.80 to 0.94), early infant mortality
was 30 or more per 1000 live births (RR 0.91; 95% CI
0.85 to 0.98), 75% or more of infant mortality occurred
in the first 6 months of life (RR 0.92; 95% CI 0.84
to 1.01), or where >32% mothers had no schooling
(RR 0.88; 95% CI 0.80 to 0.96). NVAS did not reduce
mortality in the first 6 months of life in trials conducted
in Africa, in contexts characterised by a low prevalence
of vitamin A deficiency, lower rates of infant mortality
and where maternal education was more prevalent.
There was a suggestion of increased infant mortality
in trials conducted in Africa (RR 1.07; 95% CI 1.00 to
1.15). Individual-level characteristics such as sex, birth
weight, gestational age and size, age at dosing, parity,
time of breast feeding initiation, maternal education and
maternal vitamin A supplementation did not modify the
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What is already known on this topic?
►► Vitamin A supplementation of children 6–59

months in settings where the deficiency is
a public health problem has been shown to
reduce mortality.
►► Supplementation between 1 and 5 months has
consistently been found as not beneficial.
►► Supplementation early in the neonatal period
has been observed to reduce mortality in South
Asia but not in Africa, for reasons that remain
unclear.

What this study adds?
►► Neonatal vitamin A supplementation (NVAS)

reduced infant mortality in South Asia, in
contexts where prevalence of maternal vitamin
A deficiency was of public health importance.
►► NVAS reduced mortality where there was
high infant mortality and high percentages of
mothers never attending school, conditions
typical of South Asian study sites.
►► No survival benefit, and possibly harm, was
suggested in Africa, in contexts where maternal
deficiency was milder, infant mortality was
lower, maternal schooling was longer.

Introduction

Globally, close to 6 million children under 5 died in
2015; the majority of these deaths occurred in the
first year of life.1 Despite considerable progress in
reducing child mortality over the past decade, new
interventions are needed to accelerate improvements in child survival.
Maternal and child undernutrition is a major risk
factor for child mortality, accounting for nearly half
of all under-5 deaths.2 Neonatal vitamin A supplementation (NVAS) has been considered as a potential intervention to reduce infant mortality. This
expectation was based on the benefits of vitamin A
supplementation from 6 months of age in reducing
later infant mortality and plausible biological mechanisms by which this could occur, in addition to
the observation of widespread maternal vitamin A
deficiency (VAD) in some regions of the world. The
WHO recommends periodic vitamin A supplementation for children aged 6–59 months. It has been
shown to reduce mortality by 12%–30%3–6 and
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has been implemented in more than 100 countries worldwide.7
However, trials assessing the effect of supplementation in infants
aged 1–5 months suggest there is no benefit of supplementation
in this age group.8–11 Initial randomised trials of NVAS showed
mixed results regarding their effects on improving survival. Trials
in Indonesia, Bangladesh and India found significant reductions
in mortality during the first year of life,12–14 while a small trial
from Nepal,10 a trial conducted in Zimbabwe15 16 and three trials
carried out in Guinea-Bissau17–19 found no evidence of benefit.
Two meta-analyses published in 2011 identified the same seven
randomised controlled trials,12–18 but reached different conclusions about the effects of NVAS on infant survival.20 21
The WHO convened a technical consultation in December
2008 to review the existing evidence regarding NVAS. The technical consultation concluded that there was insufficient evidence
to inform public health policy. Three additional randomised
trials were commissioned following its recommendations. The
publication of these large trials conducted in Ghana, India and
Tanzania added substantially to the evidence base. While the
trial conducted in India found a 10% reduction in mortality
through to 6 months after supplementation,22 the trials in Ghana
and Tanzania found no survival benefit.23 24 The results of these
trials were reviewed in the context of pre-existing trials at a
technical consultation led by the WHO in April 2014. At the
consultation, experts agreed that it would be important to pool
the data and explore potential reasons for differences in trial
results across sites. The trial investigators convened a working
group in September 2014 to develop the protocol and complete
this meta-analysis. The analysis plan is available on request.
Since the meeting, results from a cluster randomised effectiveness trial conducted in Pakistan were published.25 The Pakistani
investigators provided their data that have been included in the
analyses.
The objective of this paper is to present the findings on the
efficacy of NVAS in reducing mortality under 6 and 12 months
and how its effects may be modified by study population context
characteristics in order to inform the development of public
health recommendations.

Methods

Potential studies for inclusion in the meta-analysis were identified
through a systematic review that started with the examination of
two published meta-analyses of NVAS.20 21 These reviews were
updated using the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library), EMBASE, MEDLINE,
clinical trial websites, conference proceedings, donor agencies,
experts and researchers, the same search statement as in Gogia
and Sachdev’s [21] study for identification of any additional
randomised controlled trials published between 15 October
2010 and 22 February 2016. Data from a further randomised
controlled trial were included in the analysis after its publication
in June 2016.25
The primary outcomes were mortality from date of supplementation to 6 and 12 months. The secondary outcome is to
examine how its effects may be modified by study-level and
individual-level characteristics. The primary and secondary
outcomes remain unchanged during the course of the study.

Eligibility criteria and risk of bias assessment

Individual or cluster randomised trials assessing the effect of early
NVAS (25 000–50 000 IU intended to be given within the first
2–3 days of life) compared with placebo, with infant follow-up
through at least 6 months of age, were eligible for inclusion in
218

the meta-analysis. This excluded the West et al’s study as the
period of supplementation extended beyond 3 days of life.10
Risk of bias in the included studies was assessed following the
Cochrane Handbook recommendations.

Data collection process

Investigators for each of the identified trials (except the Soofi
et al’s trial25) met in France in September 2014 to develop a
harmonised pooled analysis protocol (not available in public
domain), define subgroups of interest and generate trial-specific
estimates for each subgroup. The same protocol and definitions
were used for the Pakistan trial data. For all trials, effect sizes
were provided as relative risks, except for Pakistan for which
effects were expressed as ORs.

Statistical methods

The primary outcomes were mortality from date of supplementation to 6 months and to 12 months.
To ensure comparability between studies, the effect size and
corresponding 95% CIs were non-parametrically calculated
using all randomised infants as the denominator for each individually randomised trial. Effect sizes and 95% CIs were calculated using generalised estimating equation logistic regression
model with log link and exchangeable correlation for the cluster
randomised trials. Effect sizes were calculated for each study
overall and for each of the specified subgroups.
We assessed the magnitude of heterogeneity across studies with
I2 statistics and corresponding p values. We pooled the overall
study-specific point estimates using random effects models
because of substantial heterogeneity (I2>50, p for heterogeneity <0.05) between studies. Subsequent subgroup analyses to
explore potential sources of heterogeneity were conducted using
fixed effects meta-analysis. We compared subgroups using the X2
statistical test for heterogeneity.

Subgroup analysis

We performed bivariate meta-regression by study-level characteristics to identify populations where the intervention may
have differential effects. We defined ‘study level characteristics’
as the characteristics of the target populations of the studies.
These included geographic region (Africa or Asia); prevalence of
maternal VAD which was assessed by study or extant data for a
country or region, as there being none (0%–1%) or mild prevalence (2%–9%) versus having a moderate (10%–19%) or severely
high (≥20%) prevalence, adapting cut-offs from previous WHO
guidance for assessing VAD in children26 27; early infant mortality,
that is, mortality in the control group in the first 6 months of
life (<30 per 1000 enrolled infants or ≥30 per 1000 enrolled
infants); ratio of 6-month mortality to 12-month mortality in the
control group (<75% or ≥75%); proportion of infants given the
first Diphtheria Pertussis Tetanus vaccine (DPT) dose by 6 months
(<93% or ≥93%); and proportion of women who have never
been to school (<32% or ≥32%). Maternal vitamin A moderate
or severe status was defined as 10% or more women with serum
retinol <0.7 mmol/L or 5% or more women with night blindness,
according to the WHO Global Database on Vitamin A Deficiency.28
Thresholds to categorise mortality at 6 months, ratio of 6-month
to 12-month mortality, proportion of infants given first DPT
by 6 months and the proportion of women who never attended
school were established by using the median of the distribution of
the characteristic in the total study population. Meta-analysis and
meta-regression were performed in STATA (V.13).
To further investigate potential sources of heterogeneity, we
also performed subgroup analyses by a number of individual-level
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characteristics. Subgroups of interest included: infant sex (male
or female); birth weight (<2500 or ≥2500 g); gestational age
and weight for gestational age categories (preterm small for
gestational age, term small for gestational age, preterm average
for gestational age, or term average for gestational age), age
at vitamin A supplementation (<24 hours, 24–47 hours or
≥48 hours), parity (1 child, 2–3 children or ≥4 children),
maternal education (none, primary school, secondary or more
school), time of breast feeding initiation (≤1 hour, 2–23 hours
or ≥24 hours), colostrum given (yes or no), and maternal largedose vitamin A supplementation (received or not received) and
maternal serum retinol (<1.05 μmol/L, indicating low to deficient status or ≥1.05 μmol/L, indicating adequate status).

Patient involvement

This manuscript uses data from published studies to address questions identified in consultation with public health researchers,
clinicians and nutritionists. In the contributing studies, definition
of intervention delivery and data collection opportunities considered patients’ practices and preferences. The intervention was
delivered at a single contact with the patient and was provided
free of cost to families. Prior to study initiation, community
leaders and families in the study areas were engaged by the teams
that shared information and obtained participants’ consent. At
the completion of the individual studies, consultations were held
to disseminate findings and discuss their implications.

Results

We included 11 studies from eight countries: Bangladesh, Ghana,
Guinea-Bissau (three studies), India (two studies), Indonesia,
Pakistan, Tanzania and Zimbabwe that met eligibility criteria.
These trials included a total of 163 567 infants. Nine were individually randomised, and two were cluster randomised. Six individually randomised trials had two arms, NVAS (48 000–50 000
IU) and placebo.12 14 18 22–24 One individually randomised trial
in Guinea-Bissau among low birthweight infants had a factorial design and compared NVAS (25 000 IU) with placebo
plus early BCG vaccine or on-time BCG vaccine.17 A parallel,
individually randomised trial in Guinea-Bissau among normal
birthweight infants was a three-arm trial which compared NVAS
(50 000 IU), NVAS (25 000 IU) and placebo.19 The individually randomised trial in Zimbabwe was a 2×2 factorial design
comparing NVAS (50 000 IU), maternal vitamin A supplementation (MVAS; 400 000 IU), NVAS plus maternal supplementation,
and placebo; results were published separately for mothers who
were HIV positive and HIV negative.15 16 The trial in Bangladesh was a cluster randomised trial nested within an MVAS
trial, and infants were supplemented from birth up to 30 days
of age (median age at dosing 7 hours (IQR: 2–18)).13 The trial
in Pakistan was a cluster randomised trial that compared NVAS
(50 000 IU) with placebo delivered by local health staff.25 All
identified published trials that met the intervention definition
and reported on the primary outcome of this joint analysis were
included. The risk of bias within included studies was determined to be low (figure 1). Notably, half of the included trials
published null findings and selective reporting within studies
was avoided by pooling the data specifically for purposes of this
meta-analysis.

Study characteristics

Study characteristics are summarised in online supplementary appendix A. Online supplementary appendix B provides
information on the studies’ populations and individual-level

prevalence of the effect modifiers examined. Online supplementary appendix C provides risk ratios per subgroup by site.

Results of individual studies

Four studies found reductions in infant mortality between
supplementation with NVAS and 6 months12–14 22 and seven
studies15–19 23–25 found no evidence of reduction. Regarding the
effect of NVAS on mortality through 12 months, two studies
found reductions in mortality,12 13 while the remaining eight
studies found no evidence of reduction. One trial did not
follow-up infants beyond 6 months of age.14

Synthesis of results
Overall pooled analysis

After pooling the 11 trials which reported mortality risk at
6 months, there was no evidence of a reduced risk of death; the
pooled risk ratio (RR) based on a random effects model was
0.97; 95% CI 0.89 to 1.06 (table 1 and figure 2).
After combining data from the 10 trials which reported
mortality by 12 months, there was also no evidence of a reduced
risk of death; the pooled RR calculated with a random effects
model was 1.00; 95% CI 0.93 to 1.08 (figure 3).

Pooled results stratified by study-level characteristics

Using meta-regression, we identified five variables as significantly
associated with the effect of NVAS on mortality at 6 months:
geographic region of study, prevalence of maternal VAD, control
group mortality at 6 months, ratio of 6-month to 12-month
mortality and proportion of mothers with no schooling.
Geographic region and prevalence of maternal VAD were associated with the effect of NVAS on mortality by 12 months (table 1).

Geographic region

Based on the five trials conducted in Asia, NVAS was associated
with a 13% lower risk of death until 6 months (RR 0.87; 95% CI
0.77 to 0.98). In Africa, based on six trials, the intervention was
associated with higher, but not statistically significant, risk of
death (RR 1.06; 95% CI 0.98 to 1.15). Based on four trials in
Asia which followed infants through 12 months, NVAS was associated with a 9% lower risk of infant death (RR 0.91; 95% CI
0.80 to 1.03), but this was not statistically significant. In Africa,
based on six trials, NVAS was associated with 7% higher risk of
death through 12 months (RR 1.07; 95% CI 1.00 to 1.15).

Maternal VAD

NVAS was associated with 13% lower mortality to 6 months in
the pooled results from three trials conducted in study populations where the prevalence of maternal VAD was moderate/
severe (RR 0.87; 95% CI 0.80 to 0.94), but not in the pooled
results from seven trials conducted in study populations with no
or mild deficiency (RR 1.05; 95% CI 0.96 to 1.15). We observed
similarly contrasting results regarding mortality through 12
months. In study populations where the prevalence of maternal
VAD was moderate or severe, two trials observed a 9% reduction in mortality (RR 0.91; 95% CI 0.83 to 1.00); in the seven
study populations with no or mild maternal deficiency, mortality
was 6% higher but this was not statistically significant (RR 1.06;
95% CI 0.98 to 1.15).

Control group mortality at 6 months and ratio of mortality to
6 and 12 months

Among six trials conducted in study populations where 6-month
mortality in the control group was 30 or more per 1000 live
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Figure 1 Summary of methodological quality of included studies (‘+’ indicates low risk of bias and ‘−’ indicates high risk of bias).
births, we found a 9% lower risk of death up to 6 months of
age with NVAS (RR 0.91, 95 CI% 0.85 to 0.98); but we found
a non-significant 8% higher risk of death among the five trials
conducted in populations where 6-month mortality in the
control group was under 30/1000 (RR 1.08; 95% CI 0.95 to
1.24). Further, among six trials conducted in populations where
75% or more of infant mortality occurred in the first 6 months,
there was evidence of lower mortality associated with NVAS
(RR 0.92; 95% CI 0.84 to 1.01), but this was not statistically
significant. The opposite was seen among four trials conducted
in populations where less than 75% of infant mortality occurred
in the first 6 months (RR 1.11; 95% CI 1.00 to 1.22).

Maternal education

Among four trials conducted in study populations where the
≥32% of mothers had never been to school, we found a 12%
lower risk of death in the first 6 months of life with NVAS (RR
0.88; 95% CI 0.80 to 0.96); but we found no difference in the
risk of death among the five trials conducted in populations
where <32% of mothers had never been to school (RR 1.04;
95% CI 0.92 to 1.18).

born to mothers with low to deficient (RR 0.73; 95% CI 0.51
to 1.05) and adequate status (RR 1.26; 95% CI 0.86 to 1.84),
thus suggesting effect modification. However, the RR was not
significant in either of the two subgroups (table 2).
While there was no indication that size for gestation and
maternal night blindness are significant effect modifiers, two
individual subgroups by these characteristics showed significant effects. NVAS significantly reduced the risk of death under
6 months among term small for gestational age infants (RR 0.86;
95% CI 0.77 to 0.97) but not among other subgroups by size
and gestation in pooled results from six studies. NVAS also
significantly reduced risk of death by 6 months in four studies
among infants of mothers who reported no night blindness (RR
0.90; 95% CI 0.82 to 0.98), but not significantly so in mothers
who reported night blindness (RR 0.89; 95% CI 0.64 to 1.26)
(table 2).
There was no significant benefit or harm identified for any
of the subgroups by individual-level characteristics regarding
mortality through 12 months (table 2). Online supplementary
appendix C provides information on the estimates of the effects
of NVAS on 6 and 12-month mortality for each study in the
subgroups.

Pooled results stratified by individual-level characteristics

Meta-analyses of effects of NVAS at 6 and 12 months stratified
by 11 individual-level characteristics (sex, birth weight, size
for gestation, age at dosing, parity, maternal education, time of
breast feeding initiation, colostrum given, MVAS and maternal
night blindness) did not show any significant heterogeneity
between subgroups. The only exception was stratification by
maternal serum retinol at baseline, which showed significant
heterogeneity (p=0.042) in effects of NVAS among infants
220

Discussion
The pooled effect estimates from all studies indicate that
NVAS had no overall benefit in reducing mortality through
6 or 12 months of age. A similar finding was reported by
Haider et al in their 2017 systematic review.29 However, there
was significant heterogeneity, suggesting that the effects of NVAS
on survival are influenced by study population characteristics.
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Figure 2 Pooled effect of neonatal vitamin A supplementation (NVAS) on mortality between randomisation and 6 months of age in all studies.
Most studies conducted in Asia showed benefits for survival
(RR 0.87; 95% CI 0.77 to 0.98) in the first 6 months of life,
but no significant effect at 12 months (RR 0.91; 95% CI 0.80
to 1.03). In Africa, however, none of the studies showed benefits, and the overall results could not rule out the possibility
of it causing harm (RR 1.06, 95% CI 0.98 to 1.15 for the first
6 months; and RR 1.07, 95% CI 1.00 to 1.15 for the first 12
months).

We propose that geography is a marker of differences in study
population contexts. In Asia, studies were conducted in populations with a higher prevalence of maternal VAD, higher early
infant mortality, higher proportion of infant deaths within the
first 6 months of life and lower levels of maternal schooling. In
Africa, on the other hand, study populations lived in contexts
that had a lower prevalence of maternal VAD, lower infant
mortality, lower early proportion of infant deaths in the first

Figure 3 Pooled effect of neonatal vitamin A supplementation (NVAS) on mortality between randomisation and 12 months of age in all studies.
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0.95 (0.86 to 1.05)

 Secondary school or more

a–i

44.9 (0.05)

0.97 (0.86 to 1.09)

13.3 (0.32)

0.0 (0.75)

0.0 (0.64)

0.91 (0.83 to 1.00)

31.6 (0.15)
32.0 (0.14)

1.00 (0.92 to 1.09)

0.98 (0.88 to 1.09)

9

a–k

 Primary school

 None

Maternal schooling

 ≥4 children

 2–3 children

11

0.93 (0.77 to 1.12)

Parity

 ≥48

0.99 (0.92 to 1.06)
0.93 (0.83 to 1.04)

a–k

 24–47

 <24

Age at dosing (hours)

21.1 (0.28)
0.0 (0.88)

0.87 (0.78 to 0.97)

29.6 (0.21)

0.98 (0.87 to 1.10)

1.09 (0.86 to 1.39)

52.0 (0.04)
44.8 (0.08)

 Term SGA

11

0.97 (0.89 to 1.05)
0.96 (0.89 to 1.04)

26.5 (0.19)

49.0 (0.03)

49.4 (0.03)

 Term AGA

a, c, f, h, i, j

a, b, c, f, h, i, j, k

0.93 (0.86 to 1.01)

0.99 (0.92 to 1.08)

0.97 (0.89 to 1.06)

I2 (p values)

27.7 (0.24)

6

8

a–k

a–k

Included studies* RR (95% CI)

0.94 (0.81 to 1.08)

 Preterm AGA

 Preterm SGA

Size for gestation age

 ≥2500

 <2500

Birth weight (g)

 Female

11

11

Overall

Sex

Studies (n)

Individual-level
characteristic

Mortality <6 months

0.273

0.974

0.339

0.782

0.338

0.594

0.294

0.895

0.255

4

6

6

8

10

10

5

7

10

10

P values of test
of heterogeneity Studies (n)

b, c, f, h

a, b, c, f, h, k

a, b, c, f, h, k

a–h

a–h, j, k

a–h, j, k

a, c, f, h, j

a, b, c, f, h, j, k

a–h, j, k

a–h, j, k

1.05 (0.95 to 1.16)

1.00 (0.92 to 1.09)

0.98 (0.84 to 1.14)

1.00 (0.94 to 1.05)

0.90 (0.74 to 1.08)

0.97 (0.90 to 1.05)

1.03 (0.95 to 1.12)

1.00 (0.92 to 1.09)

1.02 (0.93 to 1.11)

0.96 (0.88 to 1.05)

0.98 (0.89 to 1.09)

1.05 (0.97 to 1.13)

0.96 (0.88 to 1.04)

0.94 (0.79 to 1.12)

1.03 (0.93 to 1.14)

0.99 (0.93 to 1.05)

1.00 (0.91 to 1.10)

0.92 (0.83 to 1.02)

0.95 (0.83 to 1.09)

1.14 (0.90 to 1.45)

1.00 (0.93 to 1.07)

0.99 (0.92 to 1.08)

0.99 (0.92 to 1.06)

1.00 (0.93 to 1.07)

1.00 (0.93 to 1.08)

Included studies* RR (95% CI)

Mortality <12 months

72.2 (0.01)

62.3 (0.05)

0.0 (0.52)

35.4 (0.17)

0.0 (0.69)

0.0 (0.65)

55.8 (0.04)

53.2 (0.03)

0.0 (0.73)

43.7 (0.09)

48.4 (0.04)

3.5 (0.41)

0.0 (0.46)

0.0 (0.94)

28.0 (0.19)

25.2 (0.21)

0.0 (0.95)

3.6 (0.39)

0.0 (0.54)

4.1 (0.38)

34.6 (0.16)

36.9 (0.15)

42.8 (0.07)

46.6 (0.05)

46.3 (0.05)

I2 (p values)

0.505

0.860

0.313

0.611

0.308

0.682

0.354

0.964

0.760

Continued

P values of test
of heterogeneity

Table 2 Meta-analysis pooled risk ratios for the effect of neonatal vitamin A supplementation against a placebo on mortality through 6 and 12 months, overall and stratified by individual-level
subgroups (fixed effects)
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3
 <1.05

 ≥1.05

Maternal serum retinol
level (μmol/L)

*Studies are noted as follows: (a) Mazumder et al22; (b) Edmond et al24; (c) Masanja et al23; (d) Benn et al19; (e) Benn et al ; (f) Klemm et al13; (g) Benn et al18; (h) Malaba et al16 and Humphrey et al15; (i) Rahmathullah et al14; (j)
Humphrey et al12; (k) Soofi et al25 .
AGA, appropriate for gestational age; RR, rate ratio; SGA, small for gestational age.

0.0 (0.75)

0.0 (0.54)
0.82 (0.60 to 1.13)
a, f, h
3
0.042

0.0 (0.84)

0.0 (0.51)
0.73 (0.51 to 1.05)

1.26 (0.86 to 1.84)

a, f, h

f, i, k
3
 Yes

 No

Maternal night blindness

1.26 (0.90 to 1.77)

70.8 (0.06)

30.0 (0.23)
0.94 (0.64 to 1.37)

0.88 (0.78 to 1.00)

f, k
2
0.660
58.3 (0.09)

0.0 (0.49)
0.93 (0.65 to 1.33)

0.86 (0.77 to 0.96)

I2 (p values)
Included studies* RR (95% CI)

Mortality <6 months

Studies (n)
Individual-level
characteristic

Continued
Table 2

0.067

0.765

P values of test
of heterogeneity
I2 (p values)
Included studies* RR (95% CI)

Mortality <12 months

P values of test
of heterogeneity Studies (n)
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6 months and higher levels of maternal schooling. The differences in observed effects of NVAS between the two continents
are likely to reflect, to some extent, the underlying differences in
the contexts where populations were studied.
We found that NVAS reduced mortality in populations classified as having a moderate/severely high prevalence of maternal
VAD, defined as 10% or higher proportion of women with serum
retinol <0.7 mmol/L or 5% or more women with night blindness. Notably, all the studied populations meeting this prevalence threshold were in Southern Asia. This finding was partially
supported by meta-analysis using individual-level characteristics,
which suggested that baseline maternal retinol level may be an
effect modifier for the effect of NVAS. However, maternal night
blindness at individual level did not modify the effect of NVAS,
as maternal night blindness was treated when detected during
pregnancy in the trials.
We observed that studies conducted in contexts with higher
early infant mortality showed a significant benefit of NVAS, an
observation already made by Haider and Bhutta in their 2011
systematic review.20 The mechanisms underlying this effect of
NVAS on mortality are unclear. There are plausible ways through
which NVAS could reduce severity of infection and mortality.
Neonates in undernourished populations tend to be vitamin A
deficient by conventional plasma indicators.30 In South India,
where newborn vitamin A supplementation lowered mortality
by 22%,14 case fatality from diarrhoea and fever was reduced by
40%–50% during the first 6 months,31 possibly reflecting antioxidant and anti-inflammatory roles of vitamin A in preserving
intestinal tract defenses.32–34 In the same study, newborn vitamin
A also halved the risk of incident nasopharyngeal pneumococcal
colonisation from 2 to 4 months of age,35 suggestive of strengthened postnatal respiratory defenses. An alternative mechanism,
suggested in published literature, that may explain the differences
in Asia and Africa is that NVAS has harmful effects in females
after they receive DPT vaccine, and the proportion of infants who
receive DPT vaccine on time was higher in African study sites.36
Meta-analyses by individual-level characteristics that could be
proxies for infant vitamin A status did not support the hypothesis
that NVAS efficacy is modified by maternal or newborn baseline
vitamin A status. Low birthweight infants and preterm infants
in this analysis, either appropriate or small for gestational age,
who would have lower vitamin A stores than their normal birth
weight and term peers,37 38 did not show benefit from NVAS.
We acknowledge, nonetheless, that the data on gestational age
had limitations. Similarly, we did not find a significant benefit
of NVAS among infants whose mothers had not received postpartum MVAS. However, the validity of postpartum MVAS
programmes as a proxy for maternal vitamin A status is not clear,
as it may depend on a mother’s pre-existing level of VAD and
quality of programme implementation. In fact, a subgroup
analysis among participants in the Tanzania trial found that the
effect of NVAS was modified by both postpartum MVAS and the
amount of vitamin A that women consumed through food.39
We must acknowledge that the associations derived from
meta-regressions are observational, and do not have the strength
of causal relationships derived from randomised comparisons. This has been noted to apply particularly when averages
of patient characteristics in each trial are used as covariates in
the regression. We must also acknowledge that we conducted
many subgroup analyses, and some of the significant differences
between subgroups may have occurred by chance.
There are many strengths of this analysis. We included data
from all published trials of NVAS, bringing together information from over 160 000 newborns in eight different countries.
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The trial-specific subgroup analysis was conducted by the investigators themselves following a jointly agreed plan on using
individual data records. Study-specific relative risks for each
subgroup were calculated using the same definitions and methods
for every study, ensuring that observed heterogeneity was not
due to analytical differences in the way the effect estimates were
calculated. One major limitation is that we lack individual-level
data on the maternal vitamin A status for most mothers in the
trials. Such data would have allowed us to better examine the
hypothesis that the efficacy of NVAS is modified by maternal
vitamin A status. Although five studies assessed serum retinol in
a subset of subjects, due to the small sample sizes for each study
there was insufficient power to conduct a subgroup analysis
based on these data in two of these five studies. We did consider
analysing continuous data in meta-regression but did not take
this approach as data points were very few.
Our pooled analyses reveal the absence of an overall benefit
of NVAS on mortality, but show substantial heterogeneity in the
effect. This heterogeneity is best explained by the characteristics
of study populations’ contexts, suggesting that NVAS is beneficial
in South Asian contexts where the prevalence of maternal VAD is
moderate to severe, early infant mortality is high (exceeding
30 deaths per 1000 live births) and maternal schooling is low.
On the other hand, no benefit to survival, and even a possibility
of harm, is observed in African contexts where maternal VAD is
absent or only a mild public health concern, infant mortality is
lower, and levels of maternal schooling are higher.
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